Louise Chen
Stock Analyst at Scotiabank
(2.42)
# 1,119
Out of 4,784 analysts
297
Total ratings
41.75%
Success rate
-0.55%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $105 → $80 | $70.41 | +13.62% | 2 | Mar 20, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.89 | +534.92% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $18.18 | +202.53% | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Initiates: Sector Outperform | $150 | $88.72 | +69.07% | 1 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $54.24 | +1.40% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $2.20 | +581.82% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $28.10 | +77.94% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $4.93 | +204.26% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $6.48 | +162.35% | 1 | Mar 7, 2025 | |
| RNA Avidity Biosciences | Initiates: Sector Outperform | $70 | $31.60 | +121.52% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $11.45 | +336.68% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $12.49 | +140.19% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $1.59 | +843.40% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $23.27 | +114.87% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $37.29 | +47.49% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.77 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $69.30 | +130.88% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $69.46 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.21 | +78.50% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $163.71 | +31.33% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.85 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $89.23 | +73.71% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.38 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $822.51 | +7.60% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.05 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.37 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.11 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.14 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.39 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $205.29 | -2.58% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.70 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.94 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.44 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.26 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $637.36 | +45.13% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.00 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $7.59 | +756.39% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.68 | +635.29% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $0.84 | +2,871.59% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.25 | +227.87% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.73 | +217.86% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $0.98 | +409.16% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $1.70 | +429.41% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $5.00 | +33,749,900.00% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $448.76 | -42.51% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $15.08 | -0.53% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $2.26 | +2,112.39% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.70 | +1,076.47% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.11 | +636.50% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Mar 20, 2025
Maintains: Sector Perform
Price Target: $105 → $80
Current: $70.41
Upside: +13.62%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.89
Upside: +534.92%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.18
Upside: +202.53%
Blueprint Medicines
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $150
Current: $88.72
Upside: +69.07%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $54.24
Upside: +1.40%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.20
Upside: +581.82%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $28.10
Upside: +77.94%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.93
Upside: +204.26%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $6.48
Upside: +162.35%
Avidity Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $31.60
Upside: +121.52%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $11.45
Upside: +336.68%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $12.49
Upside: +140.19%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $1.59
Upside: +843.40%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $23.27
Upside: +114.87%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $37.29
Upside: +47.49%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.77
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $69.30
Upside: +130.88%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $69.46
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.21
Upside: +78.50%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $163.71
Upside: +31.33%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.85
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $89.23
Upside: +73.71%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.38
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $822.51
Upside: +7.60%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.05
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.37
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.11
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.14
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.39
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $205.29
Upside: -2.58%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.70
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.94
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.44
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.26
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $637.36
Upside: +45.13%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.00
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $7.59
Upside: +756.39%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.68
Upside: +635.29%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $0.84
Upside: +2,871.59%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.25
Upside: +227.87%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.73
Upside: +217.86%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $0.98
Upside: +409.16%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $1.70
Upside: +429.41%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $5.00
Upside: +33,749,900.00%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $448.76
Upside: -42.51%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $15.08
Upside: -0.53%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $2.26
Upside: +2,112.39%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.70
Upside: +1,076.47%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $6.11
Upside: +636.50%